Vical Incorporated
Records under this name other than patents Vical Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,852,610 | Compositions and methods for vaccinating against HSV-2 Lapsed on the fee record Ended Oct 7, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 7, 2022 | From the USPTO record |
| US 8,852,611 | Compositions and methods for vaccinating against HSV-2 Lapsed on the fee record Ended Oct 7, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 7, 2022 | From the USPTO record |
| US 8,840,903 | Compositions and methods for vaccinating against HSV-2 Lapsed on the fee record Ended Sep 23, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 23, 2022 | From the USPTO record |
| US 8,840,904 | Compositions and Methods for Vaccinating Against HSV-2 Lapsed on the fee record Ended Sep 23, 2022 · Low confidence | Lapsed on the fee record | Ended Sep 23, 2022 | Low confidence |
| US 8,834,894 | Compositions and Methods for Vaccinating Against HSV-2 Lapsed on the fee record Ended Sep 16, 2022 · Medium confidence | Lapsed on the fee record | Ended Sep 16, 2022 | Medium confidence |
| US 8,828,408 | Compositions and Methods for Vaccinating Against HSV-2 Lapsed on the fee record Ended Sep 9, 2022 · Low confidence | Lapsed on the fee record | Ended Sep 9, 2022 | Low confidence |
| US 8,821,890 | Influenza virus vaccine composition and methods of use Lapsed on the fee record Ended Sep 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | From the USPTO record |
| US 7,785,603 | Influenza virus vaccine composition and methods of use Lapsed on the fee record Ended Aug 31, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 31, 2022 | From the USPTO record |
| US 7,700,350 | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates Lapsed on the fee record Ended Apr 20, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 20, 2022 | From the USPTO record |
| US 8,673,317 | Codon-optimized polynucleotide-based vaccines against human Cytomegalovirus infection Lapsed on the fee record Ended Mar 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 18, 2022 | From the USPTO record |